Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 23 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/28/2007 First Published: 1/26/2003


1.		Phase II Study of 3-AP in Patients With Advanced Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				VION-CLI-024 MCC-13110, MCC-IRB-100798, NCT00054015

Last Modified: 8/22/2008 First Published: 6/23/2003


2.		Phase II Study of 3-AP (Triapine®) and Gemcitabine in Patients With Unresectable or Metastatic Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				VION-CLI-031 NCT00064051

Last Modified: 12/28/2007 First Published: 6/23/2003


3.		Phase II Study of 3-AP (Triapine®) and Gemcitabine in Patients With Metastatic Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				VION-CLI-030 MDA-ID-030143, NCT00064064

Last Modified: 6/11/2008 First Published: 12/23/2003


4.		Phase II Study of 3-AP (Triapine®) and Gemcitabine in Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 90				NCI				AECM-0803945 NCI-6254, NCT00075504, 6254

Last Modified: 4/4/2007 First Published: 12/23/2003


5.		Phase II Study of 3-AP (Triapine®) in Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				CAN-NCIC-IND161 NCI-NCIC-161, NCIC-161, NCT00075660, IND161

Last Modified: 12/12/2007 First Published: 1/23/2004


6.		Phase II Study of 3-AP (Triapine®) and Gemcitabine as Second-Line Treatment in Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				ECOG-E1503 E1503, NCT00077350

Last Modified: 6/22/2007 First Published: 1/23/2004


7.		Phase II Study of 3-AP (Triapine®) and Gemcitabine as Second-Line Therapy for Patients With Stage III or IV Recurrent Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				CTRG-LUN012 NCI-6256, NCT00077415, 6256

Last Modified: 6/22/2007 First Published: 1/23/2004


8.		Phase II Study of 3-AP (Triapine®) and Cisplatin in Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				UCCRC-12765A NCI-6285, NCT00077545, 6285

Last Modified: 4/20/2007 First Published: 2/20/2004


9.		Phase II Study of 3-AP (Triapine®) and Gemcitabine in Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				PMH-PHL-023 NCI-6271, 6271, NCT00078975

Last Modified: 7/9/2008 First Published: 3/24/2004


10.		Phase II Study of 3-AP and Cisplatin in Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				GOG-0126O NCT00081276

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute